- Home
- Publications
- Publication Search
- Publication Details
Title
Considering adjuvant therapy for stage II melanoma
Authors
Keywords
-
Journal
CANCER
Volume 126, Issue 6, Pages 1166-1174
Publisher
Wiley
Online
2019-12-24
DOI
10.1002/cncr.32585
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma
- (2019) Robyn D. Gartrell et al. CLINICAL CANCER RESEARCH
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
- (2018) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.
- (2018) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).
- (2018) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of patients at risk for metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria
- (2018) Brian R. Gastman et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma
- (2018) Axel Hauschild et al. JOURNAL OF CLINICAL ONCOLOGY
- Ultraviolet radiation–induced DNA damage is prognostic for outcome in melanoma
- (2018) Lucas D. Trucco et al. NATURE MEDICINE
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials
- (2017) Dirk Schadendorf et al. EUROPEAN JOURNAL OF CANCER
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group (E1697)
- (2017) Sanjiv S. Agarwala et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- (2017) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011
- (2016) Olaf Schoffer et al. BMC CANCER
- Epidemiology of cutaneous melanoma in Sweden-Stage-specific survival and rate of recurrence
- (2016) Julia Rockberg et al. INTERNATIONAL JOURNAL OF CANCER
- PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases
- (2016) Emanuela Veras et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
- Overall Survival and Durable Responses in Patients WithBRAFV600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
- (2016) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
- (2016) J. Liu et al. Cancer Discovery
- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials
- (2015) A. Santiago-Walker et al. CLINICAL CANCER RESEARCH
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- More People Die from Thin Melanomas (≤1 mm) than from Thick Melanomas (>4 mm) in Queensland, Australia
- (2015) David C. Whiteman et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
- (2015) Jason J. Luke et al. Oncotarget
- Treatment of Metastatic Malignant Melanoma With Vemurafenib During Pregnancy
- (2013) Aglaia Maleka et al. JOURNAL OF CLINICAL ONCOLOGY
- Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma
- (2013) Geoffrey T. Gibney et al. Nature Reviews Clinical Oncology
- Indoor Tanning — Science, Behavior, and Policy
- (2010) David E. Fisher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Melanoma Thickness Trends in the United States, 1988–2006
- (2009) Vincent D. Criscione et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now